Literature DB >> 31206801

SPNS2 promotes the malignancy of colorectal cancer cells via regulating Akt and ERK pathway.

Xinyue Gu1, Yang Jiang2, Weinan Xue1, Chengxin Song1, Yangyang Wang1, Yanlong Liu1, Binbin Cui1.   

Abstract

Colorectal cancer (CRC) is a prevalent malignant tumour that causes considerable cancer-related deaths globally. The sphingolipid transporter 2 (SPNS2), a sphingosine-1-phosphate (S1P) transporter, modulates multiple biological events including malignancy of cancer cells. In this study, the effects of SPNS2 on CRC progression were studied. We found that SPNS2 expression was significantly upregulated in CRC tissues compared to that in adjacent non-tumour tissues. To assess the role of SPNS2 in CRC cells, we performed loss- and gain-of-function experiments in SW480 and HCT116 cells, respectively. The results demonstrated that SPNS2 promoted proliferation, migration and invasion, and inhibited apoptosis in CRC cells. Additionally, SPNS2 enhanced the release of intracellular S1P, and increased S1P receptor 1 (S1PR1) and S1PR3 expression. Moreover, SPNS2 activated the Akt and ERK pathways, and the biological behaviours of SPNS2 were attenuated by Akt or ERK inhibitor in HCT116 cells. In conclusion, our results demonstrated that SPNS2 promoted proliferation, migration and invasion, and inhibited apoptosis by regulating S1P/S1PR1/3 axis and activating Akt and ERK pathway in CRC cells.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  zzm321990ERKzzm321990; Akt; apoptosis; colorectal cancer; proliferation; sphingolipid transporter 2

Year:  2019        PMID: 31206801     DOI: 10.1111/1440-1681.13124

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

1.  Long non-coding RNA HOXA-AS3 facilitates the malignancy in colorectal cancer by miR-4319/SPNS2 axis.

Authors:  Yang Jiang; Xiao-Yu Yu; Hui-Xin Sun; Xin-Yue Gu; Jing-Shu Geng
Journal:  J Physiol Biochem       Date:  2021-10-21       Impact factor: 4.158

2.  Prognostic Significance of Cytoplasmic SPNS2 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Jeng-Wei Lu; Yen-Shuo Tseng; Yu-Sheng Lo; Yueh-Min Lin; Chung-Min Yeh; Shu-Hui Lin
Journal:  Medicina (Kaunas)       Date:  2021-02-12       Impact factor: 2.430

Review 3.  Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer.

Authors:  Petra Grbčić; Mirela Sedić
Journal:  Molecules       Date:  2020-05-23       Impact factor: 4.411

Review 4.  Roles of G Protein-Coupled Receptors (GPCRs) in Gastrointestinal Cancers: Focus on Sphingosine 1-Shosphate Receptors, Angiotensin II Receptors, and Estrogen-Related GPCRs.

Authors:  Zhen Zeng; Chunxiang Ma; Kexin Chen; Mingshan Jiang; Reshma Vasu; Rui Liu; Yinglan Zhao; Hu Zhang
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

5.  High-Density Lipoproteins in Non-Cardiovascular Diseases.

Authors:  Ilaria Zanotti
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

6.  GUSBP11 Inhibited The Progression of Triple Negative Breast Cancer via Targeting The miR-579-3p/SPNS2 Axis.

Authors:  Guangbin Wu; Peilong Sun; Chunzhi Qin
Journal:  Cell J       Date:  2022-04-27       Impact factor: 3.128

7.  RNA-Seq transcriptome analysis reveals Maackia amurensis leukoagglutinin has antitumor activity in human anaplastic thyroid cancer cells.

Authors:  Suna Bektas; Engin Kaptan
Journal:  Mol Biol Rep       Date:  2022-09-04       Impact factor: 2.742

Review 8.  Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.

Authors:  Aleksandra Zeljkovic; Jelena Vekic; Marija Mihajlovic; Tamara Gojkovic; Sandra Vladimirov; Dejan Zeljkovic; Vesna Spasojevic-Kalimanovska; Bratislav Trifunovic
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

9.  Identification of m6A-Related Biomarkers Associated with Prognosis of Colorectal Cancer.

Authors:  Zhiyong Zhang; Xin Zhang
Journal:  Med Sci Monit       Date:  2021-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.